In our case series, all three patients presented with similar underlying conditions and anamnestic data, and have received antiresorptive medications (either bisphosphonates or a RANK-L inhibitor, or both) to prevent the occurrence or progression of bone metastases, secondary to prostate cancer. This evidence concerns the gene TNFSF11 and Familial prostate cancer.